Ageing Rewrites Pharma Portfolio Strategy
29 July 2026.Ageing reshapes pharma portfolios as access, evidence and delivery determine growth
Ageing reshapes pharma portfolios as access, evidence and delivery determine growth
Canada joins GCAP as Britain accelerates its next-generation combat-air strategy
Policy, platforms and manufacturing are reshaping global vaccine market opportunities
US reforms target faster production, secure supply chains, lower costs
Manufacturing readiness now determines which cell and gene therapies scale
GCAP contract tests allied ambition, industrial capacity and combat-air delivery
UK drone investment tests hybrid force design, funding and delivery
Healthcare moves home as pharma’s commercial model shifts toward patients
Patient persistence is becoming pharma’s next growth test after launch
Low-cost drones force faster procurement and resilient defence supply chains
Prevention-led pharma growth depends on earlier intervention, access and scale
Submarine delays push allies towards faster, riskier undersea autonomy bets
Healthcare growth is shifting from standard treatments to personalised patient strategies
Women’s health trials enter a more evidence-led, higher-value growth phase
AUKUS faces an industrial test as delivery risks intensify
Defence procurement shifts toward proven, integrated and operationally ready technologies
Vaccines are shifting from prevention into platforms, oncology and manufacturing-led growth
Defence ambition now depends on funding, procurement speed and capability
Pre-filled syringes shift from convenience to strategic biologics delivery platform
Defence procurement reform is reshaping readiness, investment and industrial competition